Pascal Druzgala

Pascal Druzgala has had an extensive career in the pharmaceutical industry. From 1997 to 2010, they held the position of Senior VP Research and CSO at ARYx Therapeutics. In this role, they were responsible for drug discovery and translational research activities and successfully brought four projects into clinical phase. These projects included Budiodarone, an anti-arrhythmic drug for atrial fibrillation, Naronapride, a gastro-prokinetic drug for gastroparesis, Tecarfarin, an anticoagulant for preventing blood clots and strokes associated with atrial fibrillation, and ATI-9242, an antipsychotic drug for schizophrenia.

Following their time at ARYx Therapeutics, Druzgala joined Optivia Biotechnology as Executive VP and CSO from 2011 to 2013. Pascal then moved on to Armetheon, Inc. where they served as EVP and CSO from 2012 to 2019. Most recently, in 2020, Druzgala took on the role of Chief Scientific Officer at Renexxion Ireland Ltd. Overall, Druzgala's work experience demonstrates their expertise and leadership in the pharmaceutical industry, particularly in drug discovery and development.

Pascal Druzgala obtained their Doctor of Pharmacy (Pharm.D.) degree in the field of Pharmacy from Universite de Montpellier. Pascal attended the university from 1973 to 1978. Later, they pursued a PhD in Medicinal Chemistry from the University of Florida, graduating in the years 1982 to 1985.